Micronics completes Series C financing
The Series C financing complements the company’s Series B financing that was completed earlier in 2008. The Series B was led by private investors. Together, these two financings
Life sciences and technology companies supported by the Ontario Bioscience Innovation Organization’s (OBIO) Capital Access Advisory Program (CAAP) have collectively raised more than C$1bn ($704.7m) in capital.
The collaboration will combine ZyGEM’s advanced enzymatic nucleic acid extraction technology and Advalytix’s expertise in single-cell molecular tests for life science research and diagnostic applications, said ZyGEM. Advalytix
The Horizons-AMI trial was a prospective, single-blind, randomized, multi-center study conducted in 11 countries. Patients undergoing angioplasty were randomly assigned to receive either Angiomax (bivalirudin) with provisional use